



Innovation to restore normality

Fundraising to support the
AGILE Coronavirus Drug Testing Initiative





These are extraordinary times

Coronavirus is like nothing we've seen in modern times, and normal life and society feel like a memory.

Despite the challenges, there are numerous examples of people helping in ways they never imagined.

We all have the power to make a difference to the people we know and love and to our communities and maybe even to the world.

These are extraordinary times,
now is the time to be extraordinary people.




Three months into the coronavirus pandemic, normal life has never felt so far away.
We need a plan to get it back.

We're a group of pharmacology, clinical trials, and infectious disease specialists with a plan to greatly speed-up testing of treatments for coronavirus, and ultimately find a way back to everyday life.




In our first wave of funding, we're looking to raise £3 million to launch the **AGILE Coronavirus Drug Testing Initiative**



We are in discussions with the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the World Health Organization (WHO); our trial platform is ready to start **testing new treatments immediately**




All funds will go directly to the initiative and will be managed through the **University of Liverpool**



The pandemic has quickly **overwhelmed healthcare systems** and currently lockdown is our only effective defence.

From the first few reports, to millions of cases and a world paralysed in lockdown in matter of months.





We are waiting on the first results of large-scale drug studies, which should be reporting in the next few months.

Multiple efforts are underway to find out whether any existing drugs are effective for treating COVID-19, such as remdesivir (originally developed for Ebola), lopinavir (for HIV), and hydroxychloroquine (for malaria).

- While everyone hopes these trials will report positive results, they may well not.
- And, as none of the medicines being tested were originally designed to target COVID-19, they're unlikely to be the best agents.
- There is an urgent need to test new drugs that have the potential to have the biggest impact for patients, **preventing hospitalisation, protecting our health services, and saving lives**. An effective drug would enable society to **return to normal**.



The traditional approach to finding effective drugs through clinical trials was not designed for a pandemic.

Conventional testing across three phases is not fast enough to keep up with a rapidly spreading new disease.

| Phase 1 studies | Phase 2 studies | Phase 3 studies |
|---|--|--|
| <ul style="list-style-type: none">• A few dozen people• In healthy volunteers• Tests only for safety• Lasting several months, but less than a year | <ul style="list-style-type: none">• Up to several hundred people• Continues to measure safety, but tests efficacy• Lasting several months, up to two years | <ul style="list-style-type: none">• Up to several thousand people• Continues to measure both efficacy and safety• Lasting one to three years |




Time needed to test the safety and efficacy of a new treatment is approximately 18 months

The **AGILE Coronavirus Drug Testing Initiative** is a new approach designed for pandemic drug testing.

Doctors and scientists working together in clinical trials at Liverpool, and Southampton have developed a new, fast and flexible type of study – a world first for infectious diseases.

- The AGILE Coronavirus Drug Testing Initiative uses a design called a **Bayesian Adaptive Trial Platform**, the most modern statistical method.
- It allows multiple drugs to be tested in parallel, and to **remove or add treatments faster than ever before**, based on results of safety and efficacy.
- This has the advantage of testing **more treatments, more quickly**, to find out which new drugs are suitable for large-scale testing in COVID-19 patients.



Time is critical. We have the people, the patients, promising new drugs, and our unique technology. **We now need funding** to make this happen faster than ever before.

Everyone is looking to return society to normal as quickly as possible. We need to save lives, secure jobs, and restart the world.

We are inviting you to become a first round partner and sponsor in the AGILE Coronavirus Drug Testing Initiative.

- **Our first funding target is £3 million.**
This would allow us to launch the study and start testing several promising new drugs.
- All donations will directly fund the trial through the **University of Liverpool**.
- Once funding is received, we can start trialling the **first candidates immediately** with regulatory approval, with the first results reported **within weeks**.

Thank you for your support

We look forward to addressing any of your questions in our follow-up call, and hope you will join our effort:

- To find new, better treatments for COVID-19, faster than even before.
- To save more lives.
- To relieve suffering.
- To protect our health services.
- And to restore everyday life.

Let's be extraordinary.

Fundraising efforts are supported *pro bono* by W₂O Healthcare Communications. For more details, and to discuss sponsorship, please contact **Suzanne Jacobs** (sjacobs@w2ogroup.com) and **Rebecca Lamb** (rlamb@w2ogroup.com) to arrange a meeting.